|
 Lilly will transfer its rights in India to sell, promote and
distribute its Trulicity and Humalog products, while continuing to
maintain its existing operating model for the remaining portfolio of
its products, the companies said.
The deal will allow Cipla to expand access to the drugs in the
country with the second-highest number of diabetic people in the
world. India has more than 70 million adults with diabetes,
according to government estimates.
Trulicity, a once-weekly shot to control blood sugar through the
week, is Lilly's best-selling drug that raked in sales of $1.54
billion in the second quarter. Its Humalog, a fast-acting insulin
injection, is also a key part of its diabetes portfolio.
[to top of second column] |
 "Developing strategic
partnerships to adopt different operating models
is the key to... make innovative medicines
available to more people in India," said Luca
Visini, Lilly's managing director for the Indian
subcontinent.
"Cipla has a strong local footprint and is well
established to expand access to (Trulicity and
Humalog) around India."
(Reporting by Anuron Kumar Mitra in Bengaluru;
Editing by Ramakrishnan M.)
[© 2021 Thomson Reuters. All rights
reserved.] Copyright 2021 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content |
